Anlotinib is an oral, small-molecule tyrosine kinase inhibitor that targets multiple receptors involved in tumor angiogenesis and growth, including VEGFR, FGFR, PDGFR, and c-Kit. By blocking these pathways, it inhibits tumor blood vessel formation, suppresses proliferation, and promotes apoptosis, making it effective against cancers such as advanced non-small cell lung cancer (NSCLC) and soft tissue sarcomas. Developed in China in the early 2000s, anlotinib underwent extensive preclinical and clinical studies, with trials in the 2010s demonstrating its efficacy and manageable safety profile. Today, it is recognized as a valuable multi-targeted therapy in oncology, offering an important treatment option for patients with limited alternatives.
